These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 33287224)

  • 1. Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML).
    Acharya UH; Walter RB
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations.
    Guijarro-Albaladejo B; Marrero-Cepeda C; Rodríguez-Arbolí E; Sierro-Martínez B; Pérez-Simón JA; García-Guerrero E
    Front Cell Dev Biol; 2024; 12():1376554. PubMed ID: 38694825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.
    Gurney M; O'Dwyer M
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia.
    Christodoulou I; Solomou EE
    Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
    Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia.
    Branella GM; Lee JY; Okalova J; Parwani KK; Alexander JS; Arthuzo RF; Fedanov A; Yu B; McCarty D; Brown HC; Chandrakasan S; Petrich BG; Doering CB; Spencer HT
    Front Immunol; 2023; 14():1294555. PubMed ID: 38022523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations.
    Garg S; Ni W; Griffin JD; Sattler M
    Hematol Rep; 2023 Nov; 15(4):608-626. PubMed ID: 37987319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).
    Hofmann S; Schubert ML; Wang L; He B; Neuber B; Dreger P; Müller-Tidow C; Schmitt M
    J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30736352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
    Marvin-Peek J; Savani BN; Olalekan OO; Dholaria B
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML.
    Kent A; Crump LS; Davila E
    Front Immunol; 2023; 14():1202950. PubMed ID: 37654497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Status of CAR T Cell Therapy for Leukemias.
    Harris K; LaBelle JL; Bishop MR
    Curr Treat Options Oncol; 2021 Jun; 22(7):62. PubMed ID: 34097135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?
    Damiani D; Tiribelli M
    Biomedicines; 2024 May; 12(6):. PubMed ID: 38927401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges.
    Arora S; Asawa P; Ramakrishnan A; Bachier C; Majhail NS
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):159-167. PubMed ID: 36537907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
    Bi X; Hsu J; Gergis M; Yang Y; Yi D; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):131-136. PubMed ID: 36537909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
    Fan M; Li M; Gao L; Geng S; Wang J; Wang Y; Yan Z; Yu L
    J Hematol Oncol; 2017 Aug; 10(1):151. PubMed ID: 28851445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.
    Mardiana S; Gill S
    Front Oncol; 2020; 10():697. PubMed ID: 32435621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
    Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
    Front Immunol; 2022; 13():847008. PubMed ID: 35464442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.